Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuroblastoma, Solid Tumor & Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CNTN4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CNTN4 ECD-Fc Fusion Protein (Wild-type & Mutant variants for key somatic mutations e.g., VAR_035507, VAR_035508). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View CNTN4 Products |
| Gene Delivery | CNTN4 Premade Lentivirus Particles. Full-length ORF for stable cell line construction. Preserves GPI-anchored conformation. | View CNTN4 Products |
| Benchmark Ab | Anti-CNTN4 Reference Antibody. Recombinant positive control for binding validation. | View CNTN4 Products |
| Validator | CNTN4 siRNA Set (3 unique sequences). For knockdown specificity verification. | View CNTN4 Products |
| Related Target: CNTN1 | CNTN1 (Contactin-1). Paralog with 45% sequence homology; critical for off-target screening. | View CNTN1 Products |
| Related Target: CNTN2 | CNTN2 (TAG-1). Axonal guidance family member; CNS toxicity counter-screen. | View CNTN2 Products |
| Related Target: CNTN6 | CNTN6 (Contactin-6). Fetal brain expression profile; developmental safety assay. | View CNTN6 Products |
| Related Target: APP | APP (Amyloid Precursor Protein). Direct binding partner of CNTN4 in neural and immune contexts. | View APP Products |
| Related Target: CD276 | CD276 (B7-H3). Synergistic immune checkpoint in the Ig superfamily. | View CD276 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Contactin Family Selectivity (CNTN1-6 Cross-reactivity) | Purified CNTN1-6 Ortholog Panel (>95% purity, Mass Spec Verified) for specificity screening |
| GPI-Anchor Conformation Integrity | Lentivirus-Based Stable Cell Lines; preserves native membrane topology for internalization assays |
| Species Translation (Human/Mouse/Cyno) | Ortholog Proteins Available: Human, Mouse, Cynomolgus Monkey; Sequence Verified with >90% homolog identity |
| ADC Internalization Verification | High-purity ECD-Fc (HEK293) with native glycosylation patterns; suitable for receptor-mediated endocytosis assays |
| Ligand-Blocking & Specificity Controls | Clinical Benchmark Antibodies and validated siRNA included for reliable assay calibration and off-target verification |
Live CNTN4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CNTN4 therapeutics is intensifying, with major players shifting focus from traditional mAbs to novel immunotherapies and antibody-drug conjugates (ADCs). As an emerging member of the immunoglobulin superfamily, Contactin 4 (CNTN4) has gained attention both as a tumor-associated antigen in neuroblastoma and glioblastoma and as a potential immune checkpoint in solid tumors. First-generation therapies are reaching preclinical milestones, and the next wave of R&D is targeting bispecific modalities (e.g., CNTN4 x PD-L1) designed to overcome resistance to traditional PD-1/PD-L1 blockade. The dual role of CNTN4 — oncogenic driver in neuroblastoma versus tumor suppressor in some glioma subtypes — creates complex differentiation requirements for candidate selection. Key challenges include Contactin family selectivity to mitigate CNS off-target toxicity, GPI-anchor conformation fidelity for internalization, and cross-species translation for preclinical models.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Emerging Biotechs, Academic Consortia | Neuroblastoma, Glioblastoma, Refractory Cancers | Internalization Assay (Need high-purity ECD-Fc with native glycosylation) |
| CAR-T | Research Institutions | Pediatric Solid Tumors | Cell Surface Conformation (Need Lentivirus-stable lines preserving GPI-anchor) |
| Monoclonal Ab | Early-stage Biotech | Neurodevelopmental Disorders, Solid Tumors (Immune Evasion) | Cross-Reactivity Panel (Need CNTN1-6 Homolog Panel for selectivity) |
| Bispecific (e.g., CNTN4 x PD-L1) | Top Tier Pharma, Undisclosed | Brain Metastases, Advanced Immunotherapy | Heterodimer Validation (Need Cross-reactive Abs against CNTN4 epitope) |